Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: May 16, 2024
Reporting Period: Event date May 16, 2024; Press release issued May 17, 2024.
Context: The Company entered into a material definitive agreement to raise capital through an at-the-market equity offering.
Key Financial Metrics
This filing reports on a specific financing transaction rather than periodic financial performance. Consequently, revenue, profit, cash flow, margins, and debt levels are not disclosed in this document.
| Metric | Value |
|---|---|
| Maximum Shares Authorized for Sale | 862,500 |
| Maximum Aggregate Gross Proceeds | $621,000 |
| Fixed Purchase Price per Share | $0.72 |
| Agreement Expiration Date | November 17, 2024 (or upon full sale of shares) |
Material Changes
The primary material change is the execution of a Purchase Agreement with Triton Funds LP ("Triton"). Key terms include:
- Capital Raise Mechanism: The Company may request Triton to purchase up to 862,500 shares of common stock at $0.72 per share.
- Ownership Cap: Sales are limited to prevent Triton from beneficially owning more than 19.99% of the Company's outstanding common stock.
- Price Protection: Triton has the right to reduce the number of shares purchased if the trading price on Nasdaq falls below $0.72 per share prior to closing.
- Short Selling Restriction: Triton has covenanted not to engage in short selling of the Company's stock during the term of the agreement.
Guidance, Outlook, and Risks
Management Commentary: Actual sales of shares depend on market conditions, the trading price of the common stock, and the Company's determination of appropriate funding sources. Triton has no right to require sales but is obligated to purchase upon the Company's direction, subject to agreement terms.
Conditions Precedent: Triton's obligation to purchase is conditioned on the filing of a Prospectus Supplement and the Base Registration Statement (File No. 333-256100) remaining effective.
Risks: The filing does not provide specific forward-looking guidance on operational milestones or future revenue. The primary risk relates to the dilution of existing shareholders and the potential for the offering to be limited if the stock price drops below the fixed purchase price of $0.72.
Investor Verification Checklist
- Verify the current trading price of PHIO on Nasdaq relative to the $0.72 purchase price to assess the likelihood of sales occurring.
- Confirm the filing status of the Prospectus Supplement referenced in the agreement.
- Review the Company's most recent 10-Q or 10-K to understand current cash runway and liquidity needs driving this financing.
- Monitor the 19.99% beneficial ownership limit to determine the maximum number of shares that can actually be sold under the current capitalization.